Abbott Labs Announces Executive and Director Changes
Ticker: ABT · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1800
| Field | Detail |
|---|---|
| Company | Abbott Laboratories (ABT) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, officer-departure
Related Tickers: ABT
TL;DR
Abbott Labs shakes up leadership: new directors elected, execs depart.
AI Summary
Abbott Laboratories announced on November 12, 2024, changes in its executive team. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives.
Why It Matters
Changes in key leadership positions can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and stability.
Key Players & Entities
- ABBOTT LABORATORIES (company) — Registrant
- Illinois (state) — State of Incorporation
- ABT (ticker) — Common Stock Ticker
FAQ
What specific roles have been affected by the executive changes?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' but does not specify the exact roles in this summary.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 12, 2024.
What is Abbott Laboratories' state of incorporation?
Abbott Laboratories is incorporated in Illinois.
What is the ticker symbol for Abbott Laboratories' common stock?
The ticker symbol for Abbott Laboratories' common stock is ABT.
What is the primary business of Abbott Laboratories according to the filing?
The filing lists Abbott Laboratories' Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 14.2 · Accepted 2024-11-15 16:13:33
Filing Documents
- tm2428216d1_8k.htm (8-K) — 28KB
- 0001104659-24-119717.txt ( ) — 246KB
- abt-20241112.xsd (EX-101.SCH) — 3KB
- abt-20241112_def.xml (EX-101.DEF) — 28KB
- abt-20241112_lab.xml (EX-101.LAB) — 37KB
- abt-20241112_pre.xml (EX-101.PRE) — 26KB
- tm2428216d1_8k_htm.xml (XML) — 5KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers As previously reported, Abbott has Agreements Regarding Change in Control ("Agreements") with its named executive officers. The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2024), the Agreement's term shall continue through the second anniversary of the Expiration Date. On November 12, 2024, Abbott notified the named executive officers that the term of the Agreements was extended through December 31, 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: November 15, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer